Brokerages Set Organon & Co. (NYSE:OGN) Price Target at $8.50

Shares of Organon & Co. (NYSE:OGN) have earned an average rating of “Reduce” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.50.

Several brokerages have recently weighed in on OGN. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. JPMorgan Chase & Co. lowered their target price on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Barclays upped their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Morgan Stanley lowered their price objective on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 11th.

Organon & Co. Price Performance

Organon & Co. stock opened at $6.58 on Monday. Organon & Co. has a 12-month low of $6.18 and a 12-month high of $16.08. The stock has a market capitalization of $1.71 billion, a P/E ratio of 9.27, a P/E/G ratio of 0.61 and a beta of 0.60. The firm’s 50-day moving average is $7.97 and its two-hundred day moving average is $8.37. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the firm earned $0.90 EPS. The business’s quarterly revenue was down 5.3% on a year-over-year basis. Equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd will be issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is 11.27%.

Institutional Investors Weigh In On Organon & Co.

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Organon & Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company’s stock worth $74,000 after acquiring an additional 1,265 shares during the last quarter. Rexford Capital Inc. raised its position in shares of Organon & Co. by 14.9% during the third quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock worth $122,000 after purchasing an additional 1,480 shares during the period. Amalgamated Bank lifted its holdings in shares of Organon & Co. by 1.9% during the third quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock valued at $852,000 after purchasing an additional 1,514 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Organon & Co. by 0.6% during the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its position in shares of Organon & Co. by 2.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.